Tandem Diabetes Care (NASDAQ:TNDM) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a sell rating to a hold rating in a research note issued to investors on Friday.

A number of other equities research analysts have also issued reports on TNDM. Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a hold rating to a buy rating and increased their target price for the stock from $24.00 to $37.00 in a report on Tuesday, March 26th. Citigroup raised their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of $37.00.

Tandem Diabetes Care Stock Down 1.6 %

Tandem Diabetes Care stock opened at $30.43 on Friday. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $40.92. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The company’s 50 day moving average is $29.80 and its two-hundred day moving average is $24.80.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Research analysts predict that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. RiverPark Advisors LLC purchased a new position in shares of Tandem Diabetes Care in the 4th quarter valued at $27,000. MCF Advisors LLC grew its position in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the last quarter. State of Wyoming grew its position in shares of Tandem Diabetes Care by 45.8% in the 4th quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after buying an additional 258 shares during the last quarter. Signaturefd LLC grew its position in Tandem Diabetes Care by 871.8% during the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after purchasing an additional 1,517 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after purchasing an additional 1,099 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.